Aduhelm Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Aduhelm market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to several factors, including the high prevalence of Alzheimer's disease, demographic shifts such as an aging population, the introduction of novel therapeutic products, increased government funding and initiatives, and rising investments from both private and government entities.

Growth during the market's forecast period can be attributed to factors such as the increasing prevalence of Alzheimer's disease, a rising geriatric population, a growing emphasis on early diagnosis and intervention, increasing awareness surrounding mental health issues, and expanding research and development activities. Key trends expected to shape the forecast period include the development of new technologies, novel approaches to treatment, advancements in the diagnosis and treatment of Alzheimer's patients, the integration of telemedicine, and innovations in personalized medicine and gene therapies.

The increasing prevalence of Alzheimer's disease is expected to drive the growth of the aduhelm (aducanumab-avwa) market. Alzheimer's disease is a progressive neurodegenerative disorder that results in the decline of cognitive functions such as memory, reasoning, and behavior. The prevalence of Alzheimer's is rising due to demographic, medical, and societal factors, especially with an aging population. Aduhelm is a treatment that targets and reduces amyloid-beta plaques in the brain, which are thought to contribute to the disease's progression. For example, according to the Alzheimer Society in May 2024, an estimated 982,000 people in the UK are currently living with dementia, with this number projected to rise to 1.4 million by 2040. The growing prevalence of Alzheimer's disease is thus driving demand for treatments like aduhelm, contributing to the market's expansion.

A key trend in the aduhelm market is the focus on obtaining regulatory approvals to increase the availability and accessibility of the treatment. Regulatory approvals, granted by government bodies such as the FDA in the U.S. or the EMA in Europe, are critical to ensure that a drug can be marketed and used within a specific region. Aduhelm received approval in June 2021 from the FDA for the treatment of Alzheimer's disease. Developed by Biogen, in collaboration with Eisai Co., Aduhelm works by targeting amyloid plaques in the brain, which are believed to contribute to the disease. By binding to these aggregated amyloid beta proteins, Aduhelm facilitates their removal, potentially slowing the progression of Alzheimer's disease. The approval has paved the way for Aduhelm's commercialization, increasing its market presence.

In March 2022, Biogen Inc., a US-based biotechnology firm known for manufacturing Aduhelm, entered into a strategic partnership with Eisai Co., Ltd. The collaboration focuses on the development and commercialization of groundbreaking Alzheimer's treatments, including aducanumab and lecanemab. By combining their research expertise and market presence, the partnership aims to enhance patient access and optimize the commercial potential of these innovative therapies. Eisai Co., Ltd. is a Japan-based pharmaceutical company.

Major players operating in the aduhelm market are Biogen Inc., Eisai Co. Ltd.

North America was the largest region in the aduhelm market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in aduhelm report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the Aduhelm market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Aduhelm (aducanumab) is a prescription medication developed by Biogen and Eisai Co., Ltd. It is a monoclonal antibody designed to treat Alzheimer’s disease by targeting and reducing amyloid-beta plaques in the brain, which are believed to contribute to the progression of the disease.

The main indications for aduhelm are mild cognitive impairment (MCI) and mild dementia. Mild cognitive impairment refers to a noticeable decline in cognitive functions, such as memory, attention, and reasoning, that is greater than what is expected for a person’s age but not severe enough to significantly interfere with daily activities. Aduhelm is distributed through hospitals, clinics, retail pharmacies, and specialty pharmacies, and is used by adults and geriatric patients.

The aduhelm market research report is one of a series of new reports that provides aduhelm market statistics, including aduhelm industry global market size, regional shares, competitors with an aduhelm market share, detailed aduhelm market segments, market trends and opportunities, and any further data you may need to thrive in the aduhelm industry. This aduhelm market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The aduhelm market consists of sales of products including aducanumab-avwa, Aduhelm injection, donanemab, and Aricept. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.